Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 277

1.

Case report: Calcium pyrophosphate dihydrate deposition of the temporomandibular joint diagnosed by fine-needle aspiration cytology.

Fuentes-Martinez N, Tani E, Darai-Ramqvist E, Skoog L.

Diagn Cytopathol. 2018 Jul;46(7):610-612. doi: 10.1002/dc.23895. Epub 2018 Feb 2.

PMID:
29392893
2.

Immune gene expression and response to chemotherapy in advanced breast cancer.

Foukakis T, Lövrot J, Matikas A, Zerdes I, Lorent J, Tobin N, Suzuki C, Brage SE, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Fernö M, Skoog L, Bergh J, Hatschek T.

Br J Cancer. 2018 Feb 20;118(4):480-488. doi: 10.1038/bjc.2017.446. Epub 2018 Jan 25.

3.

A Review of the Use of Fine-Needle Aspiration Biopsy of Mammary Tumors for Diagnosis and Research.

Tani E, Fuentes-Martinez N, Skoog L.

Acta Cytol. 2017;61(4-5):305-315. doi: 10.1159/000477373. Epub 2017 Jul 11. Review.

4.

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.

Nordenskjöld A, Fohlin H, Fornander T, Löfdahl B, Skoog L, Stål O.

Breast Cancer Res Treat. 2016 Nov;160(2):313-322. Epub 2016 Oct 8.

5.

Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer.

Kimbung S, Johansson I, Danielsson A, Veerla S, Egyhazi Brage S, Frostvik Stolt M, Skoog L, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Loman N, Malmström PO, Söderberg M, Walz TM, Fernö M, Hatschek T, Hedenfalk I; TEX study group.

Clin Cancer Res. 2016 Jan 1;22(1):146-57. doi: 10.1158/1078-0432.CCR-15-0487. Epub 2015 Aug 14.

6.

Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.

Sjöström M, Hartman L, Grabau D, Fornander T, Malmström P, Nordenskjöld B, Sgroi DC, Skoog L, Stål O, Leeb-Lundberg LM, Fernö M.

Breast Cancer Res Treat. 2014 May;145(1):61-71. doi: 10.1007/s10549-014-2936-4. Epub 2014 Apr 9.

PMID:
24715381
7.

Long-term breast cancer survival in Vietnamese women.

Thang VH, Skoog L, Luu HN, Van TT, Tani E.

Breast J. 2014 May-Jun;20(3):333-5. doi: 10.1111/tbj.12267. Epub 2014 Mar 27. No abstract available.

PMID:
24673847
8.

An expression signature at diagnosis to estimate prostate cancer patients' overall survival.

Peng Z, Skoog L, Hellborg H, Jonstam G, Wingmo IL, Hjälm-Eriksson M, Harmenberg U, Cedermark GC, Andersson K, Ahrlund-Richter L, Pramana S, Pawitan Y, Nistér M, Nilsson S, Li C.

Prostate Cancer Prostatic Dis. 2014 Mar;17(1):81-90. doi: 10.1038/pcan.2013.57. Epub 2014 Jan 7.

9.
10.

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer.

Weiner M, Skoog L, Fornander T, Nordenskjöld B, Sgroi DC, Stål O.

Ann Oncol. 2013 Aug;24(8):1994-9. doi: 10.1093/annonc/mdt159. Epub 2013 May 12.

11.

Ultrasound for diagnosing acute salpingitis: a prospective observational diagnostic study.

Romosan G, Bjartling C, Skoog L, Valentin L.

Hum Reprod. 2013 Jun;28(6):1569-79. doi: 10.1093/humrep/det065. Epub 2013 Mar 15.

PMID:
23503942
12.

Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer.

Fohlin H, Pérez-Tenorio G, Fornander T, Skoog L, Nordenskjöld B, Carstensen J, Stål O.

Eur J Cancer. 2013 Apr;49(6):1196-204. doi: 10.1016/j.ejca.2012.12.006. Epub 2013 Jan 8.

PMID:
23305873
13.

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit.

Bostner J, Karlsson E, Pandiyan MJ, Westman H, Skoog L, Fornander T, Nordenskjöld B, Stål O.

Breast Cancer Res Treat. 2013 Jan;137(2):397-406. doi: 10.1007/s10549-012-2376-y. Epub 2012 Dec 15.

14.

17β-Hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer.

Sivik T, Gunnarsson C, Fornander T, Nordenskjöld B, Skoog L, Stål O, Jansson A.

PLoS One. 2012;7(7):e40568. doi: 10.1371/journal.pone.0040568. Epub 2012 Jul 6.

15.

Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J.

J Clin Oncol. 2012 Jul 20;30(21):2601-8. doi: 10.1200/JCO.2011.37.2482. Epub 2012 Jun 18.

PMID:
22711854
16.

Immunocytochemistry: an indispensable technique in routine cytology.

Skoog L, Tani E.

Cytopathology. 2011 Aug;22(4):215-29. doi: 10.1111/j.1365-2303.2011.00887.x. Review.

PMID:
21771092
17.

Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.

Jerevall PL, Ma XJ, Li H, Salunga R, Kesty NC, Erlander MG, Sgroi DC, Holmlund B, Skoog L, Fornander T, Nordenskjöld B, Stål O.

Br J Cancer. 2011 May 24;104(11):1762-9. doi: 10.1038/bjc.2011.145. Epub 2011 May 10.

18.

Difference in hormone receptor content in breast cancers from Vietnamese and Swedish women.

Thang VH, Tani E, Johansson H, Adolfsson J, Krawiec K, Van TT, Skoog L.

Acta Oncol. 2011 Apr;50(3):353-9. doi: 10.3109/0284186X.2010.528791.

PMID:
21395466
19.

HER2 status in operable breast cancers from Vietnamese women: Analysis by immunohistochemistry (IHC) and automated silver enhanced in situ hybridization (SISH).

Thang VH, Tani E, Van TT, Krawiec K, Skoog L.

Acta Oncol. 2011 Apr;50(3):360-6. doi: 10.3109/0284186X.2010.547217. Epub 2011 Feb 21.

PMID:
21338271
20.

Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer.

Linderholm BK, Hellborg H, Johansson U, Skoog L, Lehtiö J.

Breast Cancer Res Treat. 2011 Jan;125(2):457-65. doi: 10.1007/s10549-010-1252-x. Epub 2010 Nov 26.

PMID:
21110084

Supplemental Content

Loading ...
Support Center